Searchable abstracts of presentations at key conferences in endocrinology

ea0094oc7.2 | Thyroid | SFEBES2023

Examining latest costs and prescribing on Liothyronine (T3) by dose levels with respect to the 2017 Competition and Market Authority (CMA) investigation into liothyronine prices and the implementation of 2023 British Thyroid Association (BTA) guidance for appropriate patients suggesting Liothyronine daily dose levels of 5-10mg at possible split dose twice day

Stedman Michael , Taylor Peter , Premawardhana Lakdasa , Okosieme Onyebuchi , Dayan Colin , Heald Adrian

Background: CMA showed price paid for liothyronine tablets rose from £15.15 in 2009 to £258.19 in 2017; a £100 million fine against suppliers was made public December 2021. BTA published guidance on use of liothyronine for appropriate patients in May 2023 suggesting daily dose 5-10mg at possible split twice day. This report investigated link between amounts and costs of T3 prescribing for different dose levels over the last 6 years.<p class=...

ea0041ep781 | Obesity | ECE2016

Bariatric surgery: a health economic perspective of the prescription costs

Paredes Silvia , Pereira Maria Lopes , Fernandes Aline , Manso Fernando , da Costa Maia , Marques Olinda , Alves Marta

Introduction: The economic burden of obesity on healthcare systems is increasing. Bariatric surgery leads to considerable weight loss and health improvement. However, this surgery is costly and doubts about its affordability have been raised. Few studies have assessed outcomes such as drug use and costs after bariatric surgery. The aim of this study was to evaluate drug consumption and costs before and after bariatric surgery.Methods: Retrospectively, da...

ea0090ep395 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Impact of Glucagon-like peptide-1 (GLP-1) receptor agonists on insulin resistance and weight as prevention of type 2 diabetes at overweight and obesity patients

Emini Merita , Kuci Nadije Morina , Begolli Ardiana Perjuci

Introduction: Obesity today is a growing epidemic throughout the world. With weight gain, the risk of type 2 diabetes and hypertension increases. With the approval of GLP-1 RA (semaglutide) by the FDA in June 2021 for weight reduction, a big push was given regarding the possibilities of obesity and especially for people at high risk of developing type 2 diabetes.Aim: To analyze the impact of semaglutide on insulin resistance and weight loss in patients w...

ea0004p12 | Clinical case reports | SFE2002

SEVERE HYPERCALCEMIACAUSED BY A VISIBLE PARATHYROID ADENOMA IN AN ADOLESCENT FEMALE

Das U , Issac H , Kanchi H , Price D , Humphrey G , Hall C

SEVERE HYPERCALCEMIA CAUSED BY A VISIBLE PARATHYROID ADENOMA IN AN ADOLESCENT FEMALEU.Das1, H Iassac1, H Kanchi1, DA Price1, GM Humphrey2 & C M Hall1Departments of 1Endocrinology and 2Surgery, Royal Manchester Children's Hospital, Manchester, Hospital Road, Manchester M27 4HA.A 16-year-old female collapsed following a 24-hour history of severe abdominal pain and vomiting. She was shocked, hypertensive (16...

ea0050s7.1 | Taking a risk on love - the endocrinology of behaviour | SFEBES2017

Risky business – when endocrinology takes over…

Gurnell Mark

The financial markets represent the largest and most intense competitive forum ever constructed. Here, according to classical economic theory, competition drives optimal allocation of capital to projects with the highest returns, thereby promoting global prosperity. However, financial markets can be volatile, cycling between ‘bull’ and ‘bear’ states, and threatening the stability of the global economy.Bull markets can morph into bubbl...

ea0050s7.1 | Taking a risk on love - the endocrinology of behaviour | SFEBES2017

Risky business – when endocrinology takes over…

Gurnell Mark

The financial markets represent the largest and most intense competitive forum ever constructed. Here, according to classical economic theory, competition drives optimal allocation of capital to projects with the highest returns, thereby promoting global prosperity. However, financial markets can be volatile, cycling between ‘bull’ and ‘bear’ states, and threatening the stability of the global economy.Bull markets can morph into bubbl...

ea0047oc39 | Innovative Theranostics | Theranostics2016

The success and failure of radioimmunotherapy for lymphoma

Wahl Richard

Two anti-CD-20 radioantibody therapies: Y-90 ibritumomab tiuxetan (Zevalin) and I-131 tositutumomab (Bexxar) were approved in the USA in the early 2000s. The safety and efficacy of both Bexxar and Zevalin were proven relative to rituximab. While Zevalin remains on the market, sales are reportedly low. Bexxar exited the market in 2014 after low sales. Bexxar cost $26K USD, ‘very expensive’ by early 21st century standards, but low compared to cancer therapies in 2016. ...

ea0056mtbs2 | (1) | ECE2018

Single-cell technologies in development and disease with a special emphasis on endocrine systems

Rizzoti Karine

Recently developed single cell technologies offer unprecedented investigations of cellular heterogeneity. While significant hurdles remain to be overcome, the field is progressing rapidly. In addition to now commonly performed genome and transcriptome analysis, it appears possible to examine the epigenome, proteome and metabolome at the single cell level. In addition, multi-omics technologies are being developed to profile simultaneously different material sources from the sam...

ea0019s86 | (1) | SFEBES2009

Jade, sex and a Chinese neolithic culture

Anderson D

I propose to take you on a journey, which started in 2000, when I bought my first Hongshan jade carving, a reproductive piece, in Hong Kong. Since then, as my collection and my obsession have grown at very low financial cost, I have been trying to fathom out why so many ‘experts’ are completely wrong about jade, and especially Neolithic jade. This corner of collecting is truly in the dark ages, where expert opinion rules over evidence, and this is providing me with t...

ea0013s16 | Thyroid and autoimmunity | SFEBES2007

TSH receptor antibodies – should we measure them and if so how?

Weetman Anthony

The debate on the utility of TSH receptor (TSH-R) measurement in the management of Graves’ patients has a long history (see for instance J Clin Endocrinol Metab 1998; 83: 3777–3785), and despite advances in assay techniques, the use of TSH-R antibodies in clinical practice is determined more by local custom and practice than evidence base. The diagnosis of Graves’ disease itself is usually straightforward and surrogates for TSH-R antibody testing, such as thyroi...